Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Trial Profile

A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bardoxolone methyl (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms LARIAT
  • Sponsors Reata Pharmaceuticals
  • Most Recent Events

    • 11 Oct 2019 According to a Reata Pharmaceuticals media release, safety data from four studies ( NCT03019185, NCT03366337, NCT02316821 and NCT02036970 will be presented at at the American Society of Nephrology Kidney Week 2019 Annual Meeting. Abstract are available on the conference website at https://www.asn-online.org/education/kidneyweek/archives/.
    • 08 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 31 May 2018 This trial has been completed in Spain (end date: 2018-05-16)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top